Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer's, Parkinson’s, migraine, and hypercholesterolemia.. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. The key to the platform is the proprietary library of UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies.
Location: United States, Texas, Dallas
Employees: 51-200
Total raised: $9.3M
Investors 2
| Date | Name | Website |
| - | Formic Ven... | formic.vc |
| - | MBX Capita... | mbxcapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.04.2022 | Grant | $9.3M | - |
Mentions in press and media 2
| Date | Title | Description |
| 07.03.2024 | Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 | - |
| 02.02.2023 | Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida | Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories ("VaxxLabs") in Cape Canaveral, Fla., as corporate headquarters CAPE CANAVERAL, ... |